ABTAbbott Laboratories
Abbott Laboratories is an Illinois corporation, incorporated in 1900. 10-K, Item 1
Deals between ABT and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement. Below: what the proxy filed 2026-03-13 reports that the one filed 2025-03-14 did not, quoted as filed.
New this year
1 newParagraphs about a deal, a person or a relative with nothing like them in the proxy filed 2025-03-14.
Approval process for related person transactions“This process is included in the Nominations and Governance Committee’s written charter, which is available in the corporate governance section of Abbott’s investor relations website (www.abbottinvestor.com). During 2025, the son-in-law of one of Abbott’s directors, Sally E. Blount, Ph. D., was employed by Abbott, and his total compensation exceeded the foregoing threshold.”
Read it in the proxy ↗
New wording of the review policy 3 paragraphs without an amount or a name
Approval process for related person transactions“Questionnaires annually distributed to Abbott’s directors and officers, • Certifications submitted annually by Abbott officers related to their compliance with Abbott’s Code of Business Conduct, or • Communications made directly by the related person to the Chief Financial Officer or General Counsel.”
Read it in the proxy ↗
Approval process for related person transactions“In determining whether to approve a related person transaction, the Nominations and Governance Committee will consider the following items, among others:”
Read it in the proxy ↗
Approval process for related person transactions“The related person’s relationship to Abbott and interest in the transaction, • The material facts of the transaction, including the aggregate value of such transaction or, in the case of indebtedness, the amount of principal involved, • The benefits to Abbott of the transaction, • If applicable, the availability of other sources of comparable products or services, • An assessment of whether the transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally, • Whether a transaction has the potential to impair director independence, and • Whether the transaction constitutes a conflict of interest.”
Read it in the proxy ↗
The whole section 5 paragraphs, proxy filed 2026-03-13
Approval process for related person transactions“It is Abbott’s policy that the Nominations and Governance Committee oversee, review, and approve any transaction in which Abbott participates and in which any related person has a direct or indirect material interest if such transaction involves or is expected to involve payments of $120,000 or more in the aggregate per fiscal year. Related person transactions requiring review by the Nominations and Governance Committee pursuant to this policy are identified in:”
Read it in the proxy ↗
Approval process for related person transactions“Questionnaires annually distributed to Abbott’s directors and officers, • Certifications submitted annually by Abbott officers related to their compliance with Abbott’s Code of Business Conduct, or • Communications made directly by the related person to the Chief Financial Officer or General Counsel.”
Read it in the proxy ↗
Approval process for related person transactions“In determining whether to approve a related person transaction, the Nominations and Governance Committee will consider the following items, among others:”
Read it in the proxy ↗
Approval process for related person transactions“The related person’s relationship to Abbott and interest in the transaction, • The material facts of the transaction, including the aggregate value of such transaction or, in the case of indebtedness, the amount of principal involved, • The benefits to Abbott of the transaction, • If applicable, the availability of other sources of comparable products or services, • An assessment of whether the transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally, • Whether a transaction has the potential to impair director independence, and • Whether the transaction constitutes a conflict of interest.”
Read it in the proxy ↗
Approval process for related person transactions“This process is included in the Nominations and Governance Committee’s written charter, which is available in the corporate governance section of Abbott’s investor relations website (www.abbottinvestor.com). During 2025, the son-in-law of one of Abbott’s directors, Sally E. Blount, Ph. D., was employed by Abbott, and his total compensation exceeded the foregoing threshold.”
Read it in the proxy ↗
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Work on ABT in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ABT/export.csv") into a cell.